Updated results from the phase 1/2 Beamion LUNG-1 study, presented at the European Lung Cancer Congress, show that the HER2-targeted therapy zongertinib achieved a 76% objective response rate and a median progression-free survival of 14.4 months as a first-line treatment for advanced HER2-mutant non-small cell lung cancer (NSCLC).
MEDICAL ONCOLOGYPHARMACOLOGY PRO < class="penci-entry-title entry-title grid-title penci_grid_title">Zongertinib a โbreakthroughโ for NSCLC with HER2 mutations